Dr. Lane is studying the mechanisms underlying the marked differences in cancer biology between men and women, including significantly increased risk for nearly every tumor type in males as well as gender-specific differences in response to targeted and conventional therapy. Dr. Lane and his team will explore cancer sex differences by harnessing innovative technologies such as single-cell RNA sequencing, sex chromosome-specific analysis methods for cancer genomic data, and novel isogenic models of sex bias in malignancy. A physician-scientist, Dr. Lane is in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School. He was awarded MD and PhD degrees from Washington University and completed a residency in internal medicine at Brigham and Women’s Hospital as well as a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.
Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, Taylor J, Kim SS, Griffin GK, Ghandi M, Li J, Li YY, Angelot-Delettre F, Biichle S, Seiler M, Buonamici S, Lovitch SB, Louissaint Jr. A, Morgan EA, Jardin F, Piccaluga PP, Weinstock DM, Hammerman PS, Yang H, Konopleva M, Pemmaraju N, Garnache-Ottou F, Abdel-Wahab O, Koeffler HP, Lane AA. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2021.